Drug puts CAR T activity on hold
German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 234 entries already.
Entries by Uta Mommert
License deal in oncolytic virotherapies
Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
Double win for Novartis
It was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only treatment developed specifically for patients with a PIK3CA mutation in HR+/HER2-advanced breast cancer.
Healthy figures from Spain
At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.
BioFIT: innovation and investors
For two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number of participants.
Oxford Nanopore wins over Amgen
Oxford Nanopore Technologies has impressed Amgen with its genetic sequencing technology. The US biopharma major has invested £50m in the Oxford-based company.
French Acticor Biotech raises €15.3m
In a Series B financing round, INSERM spin-off Acticor Biotech has raised €15.3m from European and Asian investors. The new financing will go towards the launch off the first Phase II clinical trial of its lead candidate ACT017 in acute ischemic stroke.
HiFiBiO bags immuno-oncology specialist H-Immune
Multinational biotherapeutics company HiFiBiO Therapeutics announced that it has taken over early stage biotech H-Immune Therapeutics. With the acquisition of the French Atomic Energy Commission spin-out, HiFiBiO aims to strengthen its strategic focus on targetting differenct T cell subsets and combat cancer.
Phase III success for Roche breast cancer drug
Roche has announced that in a Phase III trial, its antibody-drug conjugate Kadcyla showed improved invasive disease-free survival in breast cancer patients.
Getting ready for Brexit
As UKs departure from the EU is fast approaching, stakeholders are preparing for the disruption a hard Brexit might cause. While EMA is scaling back activities, pharma companies are stockpiling meds.